Remove Clinical Trials Remove Development Remove Genotype Remove In-Vitro
article thumbnail

Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?

Pharmaceutical Technology

According to Globaldata, it is involved in 5 clinical trials, which are ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Pharma Mar Overview Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer.

Hormones 100
article thumbnail

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

Bioengineer

Analysis of circulating tumor (ct) DNA at the time of treatment discontinuation or progression showed that 49% of patients in the AURA3 trial lacked the T790M mutation. Often, the loss of T790M is associated with the development of alternative competitive resistance mechanisms. months vs. 15.2 months, p = 0.01). months, 95% CI 1.3,

Genome 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clinical study first step towards treating respiratory syncytial virus 

Drug Discovery World

Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). .

article thumbnail

Nine new industry collaborations driving drug discovery forward

Drug Discovery World

SpyBiotech and the University of Oxford Biotechnology company SpyBiotech and University of Oxford have entered a research agreement for the development of a vaccine against Epstein-Barr virus (EBV). Studies have found that EBV triggers a range of very serious health conditions including certain cancers and multiple sclerosis.

Drugs 52